Owlin adds Consumer Sentiment & Review Data to its offering in its journey to transform risk management for Payment Service Providers
12.9.2023 16:00:00 EEST | Business Wire | Press release
Owlin, a global leader in merchant and third-party risk solutions, proudly announces its next big step in advancing the fintech industry: a new Consumer Review Data feature, specifically designed for Risk teams within Payment Service Providers (PSPs). Operational excellence becomes more important than ever for PSPs and manual review processes are often costly, reactive and inefficient. Owlin's latest offering heralds a transformative shift towards proactive, cost-effective, and highly efficient risk management.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230912980645/en/
Owlin for Consumer Review Monitoring for Payment Service Providers (PSPs) (Photo: Business Wire)
One of the standout features of Owlin's Consumer Review Feature is its unparalleled ability to detect leading risk signals, such as signs of distress (e.g., delivery- or product issues) well ahead of bigger issues like a bankruptcy event. This capability provides PSPs with a significant advantage in proactively mitigating risk, preventing potential financial disasters, and safeguarding their operations and reputation.
Furthermore, Owlin's Consumer Review Feature is a significant advantage in the world of adverse media monitoring, helping improve merchant risk management. It builds upon Owlin's already world-class monitoring solution for PSPs and it gives PSPs the tools they need to stay competitive.
Key Features and Benefits:
- Real-time Feedback and Risk Alerts - Instantly gather consumer feedback and correlate it with advanced risk signals, alerting PSPs to potential risks well in advance.
- Advanced Analytics - Utilize AI-driven insights powered by large language models to gauge sentiment, track trends, and pinpoint areas requiring risk mitigation.
- Enhanced Engagement and Trust Building - Responsively address concerns, showcase negative reviews, risk mitigating actions, and fortify trust in the PSP ecosystem.
- In-depth Risk Profiles - Craft comprehensive risk profiles based on a blend of signals and consumer feedback, ensuring that risk management decisions are data-driven and merchant-centric.
Stefan Peekel, Chief Growth Officer at Owlin, remarks, “By integrating consumer review data into risk management practices, we're giving PSPs a comprehensive tool that's been absent in the industry. It's not just about enhancing services but also about fortifying them against threats. In essence we now equip PSPs with a magnifying glass and a map. While they get a detailed view of consumer sentiment on a merchant, they also see how signals interconnect, allowing them to preempt risks and capitalize on opportunities.’’
Dedicated to innovation, Owlin keeps pushing to redefine what is possible in the domain of risk management. With this latest consumer review offering Payment Service Providers are equipped with a new set of state of the art tools to manage risk effectively and build trust for merchants and consumers.
About Owlin
Owlin is an AI-driven Third Party Risk and Merchant Monitoring solution that helps businesses feed better and faster risk insights into daily risk management workflows in real time. Owlin applies AI and Natural Language Processing to provide valuable insights hidden in the data and ensures its users don’t get lost in the wealth of information by visualizing complex data in a simple and customizable interface.
For more information, visit https://owlin.com/solutions/consumer-review-monitoring/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230912980645/en/
Contact information
Contact Owlin: Stefan Peekel, stefan@owlin.com, +1 201 932 4580
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ARIS Announced as Exclusive Process Intelligence Launch Partner for AWS European Sovereign Cloud8.6.2026 10:00:00 EEST | Press release
ARIS, the process context foundation for enterprise AI deployment, today announced its collaboration with Amazon Web Services (AWS) to support organizations navigating increasingly complex digital sovereignty requirements while accelerating AI-driven transformation. Many European enterprises face growing pressure to ensure sensitive operational and business data remains under European governance and regulatory control. Through the AWS European Sovereign Cloud (ESC), they will be able to combine advanced cloud and AI capabilities with enhanced operational separation, EU-based governance, and strict data residency controls. ARIS will support customers looking to operationalize AI safely and at scale within these boundaries by providing the process intelligence, governance, and operational context required for trusted enterprise AI deployment. “AI is moving rapidly from experimentation to operational execution, but organisations cannot scale AI without trust, visibility, and control,” sai
Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy8.6.2026 09:00:00 EEST | Press release
Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared. "PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it." Physics-accurate, radiobiologically informed planning PlanOne™ is built on a GPU-accelerated Monte Carlo dose engin
BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 07:00:00 EEST | Press release
BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels
Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 14:00:00 EEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom